BioIncept, LLC — Department of Health and Human Services STTR Phase I: NICHD

Description

ABSTRACT Perinatal hypoxic ischemic encephalopathy HIE affects to infants per every born Mortality from HIE can be up to and approximately of survivors suffer significant long term disability including cerebral palsy epilepsy and developmental disorders Damage during the acute phase of HIE is caused by a deficit in oxygen and glucose in the brain However increasing evidence indicates that secondary and tertiary phases are responsible for significant ongoing damage After an initial insult oxidative stress increases and signaling cascades lead to cell death Elevated inflammation and epigenetic changes may be present months to years after initial injury as evidenced by myelin deficits reduced plasticity and altered cell number Recently hypothermia has been used to significantly reduce mortality and developmental complications in term infants with HIE However there are several limitations to this approach Treatment must be initiated within hours of injury to reduce metabolic damage and oxidative stress and of infants still die or suffer severe disability The National Institute of Child Health and Human Development recently reported an urgent need to develop neuroprotective combination therapies to be used hours to days after the insult in combination with hypothermia A number of known neuroprotective compounds erythropoietin stem cells xenon etc are being investigated alone or in combination with hypothermia but to date none have emerged as a more effective treatment for HIE Overall there is need for new adjuvant therapies in HIE This project will test the efficacy of moderate hypothermia plus an immunomodulatory compound synthetic PreImplantation Factor sPIF in a rat model of HIE that is equivalent in development to a term human infant brain BioIncept has published data demonstrating that PIF regulates both the innate and adaptive immune response Significantly PIF reversed neurological damage in a multiple sclerosis model and protected against oxidative stress in multiple disease models Recent studies in a model of encephalopathy of prematurity showed that PIF provided protection against neuro axonal injury In this project we will first perform a short term dose ranging study with sPIF plus hypothermia to determine what dose is most effective Then we will perform a longer term comparison of the selected sPIF dose plus hypothermia combination and compare the results to hypothermia alone We will use histology neurofunctional tests and magnetic resonance imaging MRI to compare the different treatments Overall we anticipate PIF plus hypothermia will affect all injury phases and will create an additive neuroprotective effect since these treatments target different pathways Clinical translation of PIF as a first line HIE treatment is promising if these preclinical evaluations are successful as BioIncept received FDA Fast Track designation for PIF treatment of autoimmune hepatitis clinical trial began in and Yale University collaborators provide additional obstetric and clinical expertise PROJECT NARRATIVE Perinatal hypoxic ischemic encephalopathy HIE can result in newborn death or long term disability including cerebral palsy epilepsy increased hyperactivity and developmental disorders Recently hypothermia treatment has been used to significantly reduce mortality and developmental complications from HIE but of infants still die or suffer severe disability The National Institute of Child Health and Human Development NICHD recently reported an urgent need to develop neuroprotective combination therapies to be used hours to days after the insult in combination with hypothermia This project will test the efficacy of hypothermia plus a novel immunomodulatory compound Preimplantation Factor PIF to develop a more effective combination treatment to prevent brain injury